Abstract:Background and objective: Farnesoid X receptor (FXR), which is encoded by the NR1H4 gene, is a ligand-activated transcription factor and a member of the nuclear receptor (NR) superfamily. As a receptor for bile acid (BA), FXR has been shown to play a key role in the regulation of BA metabolism, lipid metabolism, and the inflammatory response. This article reviews the roles of FXR in the pathogenesis of various lung diseases, and identifies potential diagnostic indicators or therapeutic targets for these diseases. Methods: The PubMed and National Center for Biotechnology Information (NCBI) online databases were searched to retrieve relevant articles published from 2000 to 2024. Key content and findings: FXR was originally found to be expressed in BA-targeted organs, such as the liver and intestine. However, recent studies have shown that FXR is also expressed in "non-classical" BA-targeted organs, such as the lung and blood vessels. FXR is not only involved in the pathophysiology of a series of diseases of the gastrointestinal tract and liver, but is also involved in various lung diseases. Recent evidence suggests that FXR participates in the pathogenesis of lung diseases through multiple mechanisms. In addition, FXR may be a potential therapeutic target for some lung diseases. For example, FXR has been reported to promote the occurrence and development of non-small cell lung cancer (NSCLC) by inducing the expression of programmed death ligand 1 (PD-L1) and subsequently suppressing anti-tumor immunity in the tumor microenvironment. Conclusions: In this review, we summarized the current knowledge of the roles of FXR in different lung diseases. A better understanding of the roles and mechanisms of FXR in lung diseases will provide new perspectives for the treatment of lung diseases.

Farnesoid X receptor (FXR) as a potential therapeutic target for lung diseases: a narrative review

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease

Farnesoid X receptor modulators 2014-present: a patent review

Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders

FXR: structures, biology, and drug development for NASH and fibrosis diseases

The pathophysiological function of non-gastrointestinal farnesoid X receptor.

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer

Farnesoid X receptor: a potential therapeutic target in multiple organs

The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis

Update on FXR Biology: Promising Therapeutic Target?

The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer

[Progress in the Role of Farnesoid X Receptor in Metabolic Regulation and Tumor Cell Proliferation].

Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

Discovery of farnesoid X receptor and its role in bile acid metabolism

FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy

Farnesoid X Receptor (FXR): Structures and Ligands.

Farnesoid X receptor gene polymorphisms and metabolic disease

Bile acid nuclear receptor FXR and digestive system diseases

A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases